Bp Plc bought a new stake in Mylan (NASDAQ:MYL) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 53,000 shares of the company’s stock, valued at approximately $2,066,000.

A number of other hedge funds also recently added to or reduced their stakes in MYL. Pzena Investment Management LLC purchased a new stake in shares of Mylan during the first quarter worth about $283,158,000. Norges Bank bought a new position in Mylan during the fourth quarter worth approximately $166,189,000. Appaloosa LP bought a new position in Mylan during the fourth quarter worth approximately $124,941,000. Renaissance Technologies LLC bought a new position in Mylan during the fourth quarter worth approximately $57,378,000. Finally, State Street Corp boosted its position in Mylan by 7.8% in the fourth quarter. State Street Corp now owns 19,942,043 shares of the company’s stock worth $760,788,000 after buying an additional 1,446,244 shares during the last quarter. 60.89% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for Mylan (NASDAQ:MYL)

Shares of Mylan (NASDAQ:MYL) opened at 39.18 on Thursday. The stock has a market cap of $21.00 billion, a PE ratio of 39.14 and a beta of 1.14. Mylan has a one year low of $33.60 and a one year high of $50.40. The stock’s 50 day moving average price is $38.11 and its 200-day moving average price is $38.84. Mylan also saw unusually large options trading on Tuesday. Stock investors acquired 19,968 put options on the stock. This is an increase of 576% compared to the average volume of 2,954 put options.

Mylan (NASDAQ:MYL) last released its earnings results on Wednesday, May 10th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.92 by $0.01. The firm had revenue of $2.72 billion for the quarter, compared to analyst estimates of $2.81 billion. Mylan had a return on equity of 22.04% and a net margin of 2.50%. The company’s revenue was up 24.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.76 EPS. On average, equities analysts predict that Mylan will post $5.17 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/05/25/bp-plc-invests-2-066-million-in-mylan-myl.html.

MYL has been the topic of several research reports. Vetr cut shares of Mylan from a “strong-buy” rating to a “buy” rating and set a $44.68 price target on the stock. in a research report on Monday, February 6th. Zacks Investment Research upgraded shares of Mylan from a “sell” rating to a “hold” rating in a research note on Monday, February 27th. Mizuho reiterated a “buy” rating and issued a $47.00 price target on shares of Mylan in a research note on Tuesday, February 28th. Royal Bank of Canada set a $48.00 target price on shares of Mylan and gave the stock a “hold” rating in a research report on Thursday, March 2nd. Finally, Guggenheim restated a “neutral” rating on shares of Mylan in a research report on Friday, March 3rd. Two analysts have rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $51.28.

In other Mylan news, major shareholder Laboratories Abbott sold 44,000,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 23rd. The stock was sold at an average price of $41.60, for a total value of $1,830,400,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.71% of the company’s stock.

About Mylan

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

12 Month Chart for NASDAQ:MYL

Receive News & Stock Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related stocks with our FREE daily email newsletter.